Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 101130961 Publication Model: Print Cited Medium: Internet ISSN: 1474-7766 (Electronic) Linking ISSN: 14747758 NLM ISO Abbreviation: Pract Neurol Subsets: PubMed not MEDLINE; MEDLINE
Mohanraj, R 2021, ' The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. ', Lancet (London, England) . https://doi.org/10.1016/s0140-6736(21)00246-4 Lancet (London, England)
Mohanraj, R 2021, ' The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial. ', Lancet (London, England) . https://doi.org/10.1016/s0140-6736(21)00247-6 Lancet (London, England)